Filing Details

Accession Number:
0001209191-22-059727
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-05 16:57:53
Reporting Period:
2022-12-01
Accepted Time:
2022-12-05 16:57:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1845337 Day One Biopharmaceuticals Inc. DAWN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1673237 Papanek Julie Grant 2000 Sierra Point Parkway, Suite 501
Brisbane CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-12-01 4,760 $21.72 414,598 No 4 S Indirect See Footnote
Common Stock Disposition 2022-12-01 240 $22.34 414,358 No 4 S Indirect See Footnote
Common Stock Disposition 2022-12-02 5,000 $21.55 409,358 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,358 Indirect See Footnote
Common Stock 2,548,403 Indirect See Footnote
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2021.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.24 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $22.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.99 to $21.87 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
  7. Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.